PF-Atlas › Clinical Trials › NCT03813160
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Lenabasum 20 mg · Phase 3
Registry ID
NCT03813160
Phase
Phase 3
Status
Completed
Drug / intervention
Lenabasum 20 mg
Sponsor
Corbus Pharmaceuticals Inc.
Start
2018-12-17
Enrollment
176
Locations
54
About this trial
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis. Approximately 150 subjects will be enrolled in this study at about 60 sites in North America, Europe, and Asia. The planned duration of double-blind treatment with study drug is up to 52 weeks.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT03813160 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.